Creative Diagnostics Develops PLGA Nanoparticles for Manifold Bio-applications
Creative Diagnostics has launched a full range of highly uniform PLGA nanoparticles that applicable for bio-applications such as bioimaging and medical devices, drug delivery, theranostics, biomedical devices, and immunoassays.
With years of experience in the pharmaceutical and life science sector, Creative Diagnostics now launches a full range of PLGA nanoparticles with multiple sizes from 100 nm to 500 µm. These new highly uniform PLGA particles are mostly made with an L/G ratio of 50/50 and a few kinds with an L/G ratio of 75/25, which are applicable for bioimaging and medical devices, drug delivery, theranostics, biomedical devices, and immunoassays.
Nanoparticles generally refer to particles in the size range of 0.1 to 100 nm, where particles show completely novel physicochemical properties from their bulk counterpart. Considering the various applications of nanoparticles in biological and medical research, Creative Diagnostics strives to provide the most comprehensive list of nanoparticles products with different sizes and surface properties to meet bio-scientists’ needs in both research and industrial development, and PLGA nanoparticles are one of the good examples.
Poly(lactic-co-glycolic acid) (PLGA) particles are known to possess a unique ability to achieve controlled drug release, as well as to serve as excellent models for controlled degradation rate measurements. Creative Diagnostics now offers new PLGA nanoparticles for researchers focusing on study fields like cell labeling, coating materials for drugs, drug carriers, and drug delivery. New products such as the DiagPoly™ Fluorescent Poly(lactic-co-glycolic acid) PLGA Microspheres, and DiagPoly™ Fluorescent Poly(lactic-co-glycolic acid) PLGA Nanoparticles are all available at Creative Diagnostics.
"Creative Diagnostics focuses on nanoparticle products for research applications. We're pleased to introduce these new PLGA nanoparticles products and related services for all researchers to address scientific issues. As a leading provider of various nanoparticle tools, Creative Diagnostics will continue to keep close collaboration with scientists and provide expert support to the global researchers." said Dr. Jessica Waldorf, chief scientific officer of R&D department, at Creative Diagnostics.
"We are excited to expand our nanoparticles offerings to the global research communities, as Creative Diagnostics is always committed to offering widely applicable and technically successful products and services to our customers. As a research tool, these PLGA nanoparticles are easy to use and will bring our customers more successful project results, and it’s great to make some contributions to their scientific research and development." said Alex, one of a senior scientific officers at Creative Diagnostics.
Read the original article on PharmiWeb.